Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a
persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the …

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

B cells are increasingly recognized as playing an important role in the ongoing control of
hepatitis B virus (HBV). The development of antibodies against the viral surface antigen …

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B
cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately …

Chronic HBV (CHB) infection suppresses virus-specific T cells, but its impact on humoral
immunity has been poorly analyzed. Here, we developed a dual-staining method that …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …

Antibodies are an important component in host immune responses to viral pathogens.
Because of their unique maturation process, antibodies can evolve to be highly specific to …

“Functional cure” is being pursued as the ultimate endpoint of antiviral treatment in chronic
hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs …

While new therapies for chronic hepatitis C virus infection have delivered remarkable cure
rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal …

Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the
progression to cirrhosis and hepatocellular carcinoma, which are serious public health …